Biopharmaceutical development is not limited by our ability to design products that work, but rather by our capability to make them. This talk will discuss how we move beyond the undesirable situation where many promising molecular formats are considered too difficult to manufacture. With a particular focus on the implementation of synthetic biology technologies, I will present new approaches for designing bioproduction systems that are fit for the manufacture of complex, engineered next-generation products.
